Diroximel fumarate 是一种控释制剂，是口服具有活力的富马酸单乙酯的前体药物。它被认为与其活性代谢物富马酸二甲酯的活性等效。它具有良好的安全性和有效性，具有研究多发性硬化的潜力。

Diroximel fumarate, a prodrug of monomethyl fumarate in a controlled-release formulation, rapidly and potently converts to MMF in the body.

The kinase reaction system contains BMX or BTK, 1 μL of serially diluted CHMFL-BMX-078, and substrate Poly peptidewith 100 μM ATP. The reaction in each tube is started immediately by adding ATP and kept going for an hour under 37 °C. After the tube cooled for 5 min at room temperature, 5 μL solvent reactions are carried out in a 384-well plate. Then 5 μL of ADP-Glo reagent is added into each well to stop the reaction and consume the remaining ATP within 40 min. At the end, 10 μL of kinase detection reagent is added into the well and incubated for 30 min to produce a luminescence signal. Luminescence signal is measured with an automated plate reader.

1577222-14-0

C11H13NO6

255.22

Diroximel Fumarete;Diroximel fumarate

DMSO:125 mg/mL (489.77 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years